Another RA-backed biotech hits Nasdaq as public market stirs again after a bruising first quarter

California’s AN2 Therapeutics has been on a roll recently.

The lung disease biotech raised $80 million in a Series B back in January, announcing it in the company’s first press release since its series A round in 2019. At the time, big backers included RA Capital Management, a VC firm that’s shown a penchant for helping biotechs make quick jumps to the public market.